Edwards Lifesciences Corporation
EW
Classement en actions
#485
Edwards Lifesciences Corporation is a global medical technology firm... Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
Prix de l'action
$88.21
Capitalisation boursière
$50.84B
Changement (1 jour)
1.05%
Changement (1 an)
17.16%
Pays
US
Échange Edwards Lifesciences Corporation (EW)
Catégorie
Healthcare
Ratio P/E pour Edwards Lifesciences Corporation (EW)
Ratio P/E au October 2026 TTM : 49.68
Selon les derniers rapports financiers et le cours de l'action de Edwards Lifesciences Corporation, le ratio P/E actuel (TTM) est de 49.68. À la fin de l’année 2024, le P/E de l’entreprise était de 10.60.
Historique du ratio P/E pour Edwards Lifesciences Corporation de 2000 à 2026
Ratio P/E à la fin de chaque année
| Année | Ratio P/E | Changez |
|---|---|---|
| 2026 (TTM) | 49.68 | 6.99% |
| 2025 | 46.44 | 338.15% |
| 2024 | 10.60 | -67.87% |
| 2023 | 32.99 | 8.70% |
| 2022 | 30.35 | -43.51% |
| 2021 | 53.72 | -22.12% |
| 2020 | 68.98 | 48.61% |
| 2019 | 46.42 | 4.62% |
| 2018 | 44.37 | 16.12% |
| 2017 | 38.21 | 9.03% |
| 2016 | 35.04 | 1.90% |
| 2015 | 34.39 | 105.62% |
| 2014 | 16.73 | -10.81% |
| 2013 | 18.75 | -46.93% |
| 2012 | 35.34 | 3.23% |
| 2011 | 34.23 | -18.82% |
| 2010 | 42.16 | 97.55% |
| 2009 | 21.34 | -10.28% |
| 2008 | 23.79 | 2.00% |
| 2007 | 23.32 | 10.59% |
| 2006 | 21.09 | -32.57% |
| 2005 | 31.27 | -97.84% |
| 2004 | 1.45K | 6,328.22% |
| 2003 | 22.50 | -16.59% |
| 2002 | 26.98 | -119.89% |
| 2001 | -135.62 | 3,477.63% |
| 2000 | -3.79 | 0.00% |
Ratio P/E pour des entreprises similaires ou concurrentes
| Entreprise | P/E Ratio | Différence du P/E Ratio | Pays |
|---|---|---|---|
| 33.11 | -33.36% |
US
|
|
| 21.39 | -56.95% |
IE
|
|
| 28.94 | -41.74% |
US
|
|
| 17.34 | -65.10% |
US
|
|
| - | - |
DE
|
Comment lire un P/E ratio ?
Le ratio Prix/Bénéfice (P/E Ratio) mesure la relation entre le cours de l'action d'une entreprise et ses bénéfices par action.
Un P/E bas mais positif indique une entreprise qui génère des bénéfices élevés par rapport à sa valorisation et qui pourrait être sous-évaluée. Un P/E négatif élevé (proche de 0) indique des pertes importantes.
Les entreprises avec un P/E supérieur à 30 ou négatif sont généralement considérées comme des "actions de croissance", ce qui signifie que les investisseurs s'attendent à ce qu'elles se développent ou deviennent rentables.
Les entreprises avec un P/E positif inférieur à 10 sont généralement considérées comme des "actions de valeur", car elles sont déjà très rentables mais avec peu de potentiel de croissance.